Baicalin and baicalein attenuate hyperuricemic nephropathy via inhibiting PI3K/AKT/NF‐κB signalling pathway

BA and BAI were confirmed to attenuate HN through alleviating renal inflammatory and apoptosis in cells and tissues by inhibiting PI3K/AKT/NF-κB pathway. BA and BAI were expected to be developed as new anti-HN drugs.